Thalidomide for the treatment of multiple myeloma.

Congenital anomalies

Volumn 44, Issue 3, 2004, Pages 125-136

  Hattori, Yutaka ^a   Iguchi, Toyotaka ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DEXAMETHASONE; DRUG DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; THALIDOMIDE; VASCULOTROPIN A;

BLOOD; HUMAN; METABOLISM; MULTIPLE MYELOMA; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16644369523     PISSN: 09143505     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1741-4520.2004.00025.x     Document Type: Review

References (73)